Categories AlphaGraphs, Earnings, Other Industries

Cancer drugs lift Johnson & Johnson’s sales in Q1

Pharmaceutical giant Johnson & Johnson (JNJ) reported a 12.6% increase in sales to $20 billion for the first quarter of 2018 as domestic sales grew 6.1% and those from international markets improved about 20%. The increase in worldwide revenues was fuelled by strong pharmaceutical sales led by cancer drugs Imbruvica and Darzalex.

Net earnings fell slightly to $4.4 billion or $1.60 per share compared to the prior-year period. After adjusting for certain special items, net earnings amounted to $5.6 billion, or $2.06 per share, beating analyst expectations.

Worldwide Consumer sales increased 5.3%, while worldwide Pharmaceutical sales rose 19.4% during the first quarter of 2018. Medical Devices segment saw 7.5% growth during this period, compared to the prior-year period.

JNJ Q1 2018 Earnings

Blood-cancer treatments Imbruvica and Darzalex saw revenue growth, excluding currency, of 35% and 64% respectively while rheumatoid arthritis medication Remicade came under pressure with an 18% drop in sales.

The tax reform has given the company an opportunity to raise its R&D and capital investments in the US by 15% over the next four years. Johnson & Johnson is also planning to restructure its global supply chain in order to generate as much as $800 million in annual pre-tax savings by 2022. The consumer products firm also expects to relaunch its baby care business later in 2018.

During Q1 2018, Johnson & Johnson completed the acquisition of software-enabled surgery technologies developer Orthotaxy S.A.S. The company also received an offer of about $2.1 billion for its LifeScan business from private investment firm Platinum Equity.

The tax reform has given the company an opportunity to raise its R&D and capital investments in the US by 15% over the next four years.


The pharma giant increased its sales outlook for full-year 2018 to a range of $81 billion to $81.8 billion. This reflects an operational growth of 4% to 5%. Adjusted EPS is projected to be $8.00 to $8.20, reflecting an operational growth of 6.8% to 9.6%.

JNJ stock rose around 1% in premarket trading.

Most Popular

Stock Watch: Is Darden Restaurants a good buy after earnings?

After a prolonged slowdown, the restaurant industry is returning to normal patterns but macroeconomic uncertainties and high inflation are currently playing spoilsport for it. While the pandemic-related slump forced many

Lennar (LEN) believes that despite near-term challenges, the long-term prospects for housing remain strong

Shares of Lennar Corporation (NYSE: LEN) were down 3% on Monday. The stock has dropped 36% year-to-date and 25% over the past 12 months. The homebuilder delivered mixed results for

KB Home (KBH): What did and did not work for the homebuilder in the third quarter

Shares of KB Home (NYSE: KBH) were up slightly on Friday. The stock has dropped 40% year-to-date and 35% over the past 12 months. The company delivered mixed results for


Add Comment
Viewing Highlight